Statistical considerations in a delayed-start design to demonstrate disease modification effect in neurodegenerative...

Area of Science:

• Neuroscience
• Clinical Trials
• Biostatistics

Background:

• The diagnosis and treatment of neurodegenerative diseases like Alzheimer's disease (AD) and Parkinson's disease are shifting towards early intervention based on biological changes preceding clinical symptoms.
• Biomarker-driven enrichment strategies are crucial for therapeutic drug development in early-stage AD.
• Demonstrating disease modification (DM) in neurodegenerative disorders is challenging due to the lack of suitable biomarkers and clinical endpoints.

Purpose of the Study:

• To propose a new analytical approach for evaluating disease modification (DM) effects in neurodegenerative disorders using a delayed-start trial design.
• To address the limitations of traditional analytical methods that assume linear responses within each treatment arm.
• To enable the detection of lasting treatment benefits even with patient heterogeneity in response timing and magnitude.

Main Methods:

• Utilizing a delayed-start design with two treatment periods: initial randomization to active treatment or placebo, followed by a crossover for the placebo group.
• Applying a novel analytical approach that assumes linearity for treatment differences but not necessarily for individual arms.
• Accounting for the heterogeneity in the timing and magnitude of maximal treatment effects among patients.

Main Results:

• The proposed method allows for the evaluation of disease modification effects by analyzing treatment differences over time.
• It accommodates nonlinear responses within treatment arms, which are common in neurodegenerative disease trials.
• This approach aims to provide a more robust assessment of lasting therapeutic benefits compared to traditional methods.

Conclusions:

• The proposed analytical approach offers a more flexible and accurate way to demonstrate disease modification in neurodegenerative disorders.
• This method is particularly valuable for trials involving early intervention and complex patient responses.
• It supports the development of effective treatments for conditions like Alzheimer's and Parkinson's disease by better evaluating drug efficacy.